Wheeler Bio Announces Closing of $31 Million Series A Round Supporting its Clinical (CGMP) Drug Substance Manufacturing Facility in Oklahoma City

Wheeler Bio, a CDMO specializing in therapeutic antibodies, has closed its Series A funding round, co-led by Charles River Laboratories and Echo.

The firm’s Portable CMC is an open-source middleware that enhances the gene-to-IND supply chain, delivering speed, efficiency, predictability, and freedom to operate. The firm intends to complete a 500L scale CGMP cell banking and drug substance manufacturing facility in Oklahoma City, with the first batches of production set to commence in Q3 2023. The new facility will utilize integrated tools and technologies like Solentim, Ambr Microbioreactors, and DynaDrive Single-Use Bioreactors.

Read more at Wheeler Bio

Share

Related Posts